News | November 20, 2021
U.S. FDA allows Pfizer and Moderna booster doses for all
This is a shot in the arm for the vaccine manufacturers
This is a shot in the arm for the vaccine manufacturers
Support from DFC will help produce one billion vaccine doses by the end of 2022
The authority also allowed mix and match of booster doses once the primary vaccine has been administered.
U.S. FDA to decide whether to authorize a booster dose in the coming days
The first study to investigate the safety and immunogenicity of both vaccines when co-administered compared to each vaccine administered separately in adults aged 65 years and older
A growing number of studies have shown the benefit of a third dose of Covid-19 vaccine in immunocompromised subjects
Emergency Use Authorisation (EUA) is granted for individuals 65 years of age and older, and individuals ages 18 through 64 within certain high-risk groups
New interim data from these studies demonstrate that a booster dose of the Johnson & Johnson Covid-19 vaccine generated a rapid and robust increase in spike-binding antibodies, nine-fold higher than 28 days after the primary single-dose vaccination.
The submission to the US FDA has been initiated and they intend to file these data with the European Medicines Agency and other regulatory bodies in the coming weeks
The data suggest that a booster dose given within 6 to 12 months after the second dose may help maintain a high level of protection against COVID-19.
Subscribe To Our Newsletter & Stay Updated
